Hier findet Ihr Entry into a Material Definitive Agreement: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7821458
News vom 28.3.2011
BioPharm Asia in Negotiations to Acquire Hubei Holley Zhengyuan Pharmaceutical Company Limited
NEW YORK & TONGHUA, China, Mar 28, 2011 (BUSINESS WIRE) -- BioPharm Asia, Inc. (OTCBB: BFAR) (the "Company") announced today that it is negotiating to acquire a controlling interest in Hubei Holley Zhengyuan Pharmaceutical Company Limited ("HBHLZY").
HBHLZY, founded in November, 2004, is a wholesale distributor of pharmaceutical products, located at the CBD of Wuhan city, Hubei province. HBHLZY's facilities consist of packaging equipment and a logistical management system. HBHLZY sells 4580 types of products, from 652 suppliers in China and in particular, Hubei province. HBHLZY also acts as a sales agent for over 2000 types of products, including products from Shenzhen SanJiu Pharmaceutical Co., Ltd. and Shenzhen Zhijun Pharmaceutical Co., Ltd.
About BioPharm Asia, Inc.
BioPharm Asia, Inc. is engaged in the retail sale of medicinal and herbal products in China, complemented by vertically integrated supporting functions that include the cultivation of Chinese herbal medicines, pharmaceutical production and wholesale medicine distribution. Following several successful acquisitions, the Company is completing the integration of its distribution channels and expanding its trading business (conducted through its retail stores as well as its distribution activities) to include pharmaceutical manufacturing and the cultivation and sale of medicinal raw materials. The company has a plan to use the funds proceeds from sale of S&T and its subsidiary Silin to acquire HBHLZY. For more information, please visit http://www.biopharmasiainc.com.
Forward-looking statement: Except for certain historical information contained herein, the matters discussed in this news release contain forward-looking statements, including, but not limited to, statements relating to future acquisitions, expansion plans and growth in sales. These forward-looking statements involve a number of risks and uncertainties. Actual results may differ materially from those implied herein due to a number of factors, including, but not limited to, uncertainties in product demand, risks related to doing business in China, the impact of competitive products and pricing, changing economic conditions around the world, release and sales of new products and other risk factors discussed in the company's most recent annual report and other filings with the U.S. Securities and Exchange Commission.
SOURCE: BioPharm Asia, Inc.
CONTACT:
BioPharm Asia, Inc. Xia Yang Hu, 011-86-435-5211804 rodgerhu@biopharmasiaco.com
Copyright Business Wire 2011
-0-
KEYWORD: United States China Asia Pacific North America New York INDUSTRY KEYWORD: Health Alternative Medicine Biotechnology Pharmaceutical SUBJECT CODE: Merger/Acquisition
Ein paar Infos zu der neuen Akquisition gibt es hier!
Shenzhen Zhijun Pharmaceutical Co.,Ltd 1company with 137.2Mil USD (RMB900Mill) assets, annual sales 182.93Mil USD (RMB1,200Mill). See profile below and from company website @http://szzhijun.com/english/about.aspx?id=25
Formerly named Shenzhen Pharmaceutical Factory, Shenzhen Zhijun Pharmaceutical. Co.ltd was established in 1985, playing a key role in SINOPHARM cephalosporin manufacturing lineup and also representing the core manufacturing enterprise in Shenzhen Accord Pharm.
With over 20 years’ endeavor, Zhijun has developed into a national High-Tech Enterprise focusing on Quality, Efficiency and Technology, with total assets equal to RMB900 million, annual turnover reach RMB1,200 million, and annual interest duty over RMB 100million. Now Zhijun has grown to a National Hi-Tech Enterprise among the list of Top 50 Pharmaceutical Factory in China.
Zhijun is strong in manufacturing Respiratory and Anti-infective pharmaceutical products, owns an international standardized R&D premise of 45,000 square kilometers, 9 production lines within 5 workshops which are powder for injection, oral solution and oral solid ( for cephalosporins and non-cephalosporins ). The company is in line with the EU GMP quality management, produced a series of market leading products with stringent quality control and management system and powerful marketing network. DaliXin (Cefuroxime axetil tablets and capsules) is the best player, leading the Dali brand and Zhijun brand to the top of the marketplace. The company is expanding the business in overseas markets and building strong reputation profile in global marketplace.
The Zhijun Product line has extended to the healthcare and OTC products. In the near future, Zhijun Pharma will take advantage of the SINOPHARM manufacture and sales integration, combine the API supplying to reduce the production cost and expand the scale, thus driving itself to be the core enterprise in the China Pharmaceutical Group Manufacturing lineup. |